Andrews Mark, Brown Alan, Chiva Jean-Yves, Fradet David, Gordon David, Lansdell Mark, MacKenny Malcolm
Discovery Chemistry, Pfizer Global Research and Development, Sandwich, United Kingdom.
Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. doi: 10.1016/j.bmcl.2009.02.054. Epub 2009 Feb 20.
The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs.
已报道的选择性5-羟色胺再摄取抑制剂利托西汀被用作一系列具有高合成可及性的潜在选择性5-羟色胺再摄取抑制剂设计的起点。制备及后续优化产生了一系列强效且高度选择性的选择性5-羟色胺再摄取抑制剂。